Women with PMOS should get subsidised weight loss drugs, advocates say
Summary
Advocates in Australia want weight loss drugs called GLP-1s to be subsidized for women with a hormonal condition named Polyendrocrine Metabolic Ovarian Syndrome (PMOS). This condition affects many women and can cause health problems like diabetes and heart disease. Although these drugs are not officially approved for PMOS, some patients use them and face high costs.Key Facts
- PMOS affects about 1 in 8 women and causes symptoms like irregular periods, excess hair growth, weight gain, and hair thinning.
- PMOS increases the risk of diabetes, heart disease, and some cancers.
- GLP-1 drugs help control blood sugar and reduce hunger but are not officially approved for PMOS treatment.
- Many women use GLP-1 drugs off-label (for a use not formally approved) and pay several hundred dollars a month.
- The Pharmaceutical Benefits Scheme (PBS) currently subsidizes some GLP-1 drugs for diabetes, not for PMOS.
- The Pharmaceutical Benefits Advisory Committee is reviewing proposals to subsidize one GLP-1 drug, Wegovy, for obesity.
- Medical experts say more research is needed before GLP-1 drugs can be routinely used for PMOS.
- Advocacy groups stress the importance of fair access to these medications for all patients, regardless of location or background.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
